Alife is a technology company.
Alife has raised $32.0M across 2 funding rounds.
Alife has raised $32.0M in total across 2 funding rounds.
Alife has raised $32.0M in total across 2 funding rounds.
Alife's investors include Alt Capital, A'Z Angels, Collab Capital, Dunce Capital, Floodgate, General Catalyst, Infinity Ventures, Initialized Capital, Kapor Capital, Lux Capital, Maveron, Obvious Ventures.
Alife Health is a San Francisco-based technology company founded in 2020 that builds AI-powered software to modernize and personalize in vitro fertilization (IVF) processes for fertility clinics.[1][2][3] It serves IVF clinics, embryologists, and patients by providing tools like Embryo Assist for embryo grading and cataloging, analytics dashboards for performance monitoring, and patient-facing reports with embryo images and clinical insights, addressing inefficiencies in clinic operations, inconsistent decision-making, and suboptimal patient outcomes.[1][3][4][5] The company has raised $22 million in Series A funding from investors including Lux Capital, Maveron, and Union Square Ventures, partnered with nearly 20 top U.S. clinics including US Fertility, and earned recognitions like Fast Company's Most Innovative Companies of 2024.[2][3][4][5]
Alife's growth momentum includes a nationwide rollout with US Fertility in late 2024, piloting and deploying its platform across their labs to enhance efficiency and patient engagement, positioning it as a leader in AI-driven reproductive health tech amid rising IVF demand.[4][5][6]
Alife Health was founded in 2020 by Paxton Maeder-York, its CEO, who launched the company to bring advanced analytics and AI to the IVF sector after identifying gaps in clinic operations and patient care.[3] Maeder-York led two years of R&D before launching its core AI platform, focusing on productizing large-scale research data into clinically usable tools for embryo selection, ovarian stimulation, and performance tracking.[1][3] Early traction came from partnerships with top fertility clinics to collect and train on vast datasets, enabling rapid iteration; by 2024, it secured Series A funding and accolades, with Melissa Teran stepping in as CEO to scale commercial adoption.[2][3][4]
Pivotal moments include collaborations with nearly 20 leading U.S. clinics for AI training and testing, followed by high-profile pilots like the November 2024 partnership with US Fertility, the largest physician-owned network, which validated its tech in real-world labs.[3][4][5]
Alife rides the convergence of AI advancements and surging IVF demand, driven by delayed parenthood, medical infertility, and expanding insurance coverage, with U.S. clinics handling growing volumes amid labor shortages.[3][5] Timing is ideal post-2020 fertility tech boom, as AI scales beyond human limits in embryo analysis—analyzing millions of parameters for better outcomes—amid market forces like clinic consolidation (e.g., chains wrapping 500+ sites).[1][3] It influences the ecosystem by setting standards for AI in reprotech, partnering with leaders like US Fertility to nationwide-rollout tools that lower costs, streamline workflows, and personalize care, potentially accelerating adoption across global clinics.[4][5][6]
Alife is poised for expansion with its US Fertility nationwide deployment, likely driving revenue through subscriptions and data insights while pursuing clinical studies for new products.[3][5] Trends like generative AI integration, larger datasets from partnerships, and regulatory tailwinds for fertility tech will shape its path, potentially capturing significant share in a fragmented market.[2][3] Its influence may evolve from clinic enabler to full IVF platform, influencing outcomes for millions as AI becomes standard in reproductive health—modernizing a field ripe for disruption, much like its founding vision to personalize care for all.[1][2]
Alife has raised $32.0M across 2 funding rounds. Most recently, it raised $22.0M Series A in March 2022.